Cinclus Pharma Holding Ab · OMXSTO:CINPHA
Cinclus Pharma Holding Ab — Q2 2024 Earnings Presentation
16 slides from Cinclus Pharma Holding Ab's earnings presentation, Aug 29, 2024
Slide 1: Cinclus Pharma Q2 Report 2024
Cinclus Pharma Q2 Report 2024 Webcast August 29, 2024, 13:00 Presenters: Christer Ahlberg, CEO Maria Engström, CFO 1
Slide 2: Disclaimer
Disclaimer IMPORTANT: You must read the following before continuing. The following applies to this and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”), a “qualified document, the oral presentation of the information in this document by Cinclus Pharma Holding investors” fal
Slide 3: Focus on the unmet medical need, where 24 hr acid control is most important
Focus on the unmet medical need, where 24 hr acid control is most important Focus on Healing of Severe Linaprazan glurate Patients, the Unmet Potential to become best in Medical Need in eGERD class and the first innovative Enables Specialty Commercial Focus HQ: Stockholm, MoA 1) in gastric acid rela
Slide 4: Blockbuster market potential in severe eGERD in USA & EU
Blockbuster market potential in severe eGERD in USA & EU GERD 705m – USA and EU-30 approachable population1) 133m – GERD population (~19% of general population) 92.5m – Proportion seeking treatment (70%) eGERD 27.7m 30% Proportion of eGERD patients seeking treatment patients 10m 36% All eGERD C/D -
Slide 5: Linaprazan glurate: Potential to be best in class 2nd generation PCAB
Linaprazan glurate: Potential to be best in class 2nd generation PCAB PHARMACOLOGICAL (PRODRUG) ADVANTAGES PROVIDES… … CLINICAL ADVANTAGES AND SUPERIORITY PROFILE HEALING EFFECT SUPERIOR DAY- SUPERIOR NIGHT- DOSING TIME TO DIFFERENCE TIIME TO SUPERIORITY IN TIME SYMPTOM TIME SYMPTOM INDEPENDENT TIME
Slide 6: Specialist GI targeted commercialization approach maximizes Cinclus Pharma optionality post-data
Specialist GI targeted commercialization approach maximizes Cinclus Pharma optionality post-data Severe eGERD Effective go-to-market approach Specialist GI approach (LA Grade C/D patients) Effective market entr y ▪ Specialist GI approach… Accessible with a highly focused sales & The concentrated Spe
Slide 7: Initial Indication aspiration
Initial Indication aspiration … Accomplished 24hr pH control in clinical studies …Aiming to show superior Healing in severe eGERD (C&D) Treatment of erosive With focus on … Aiming to show superior Gastro- esophageal healing of symptom control with focus on reflux disease severe eGERD night time symp
Slide 8: Strategic roadmap with dense upcoming news flow
Strategic roadmap with dense upcoming news flow Description 2024 2025E 2026E 2027E 2028E 2029E 1st Phase III 1st Phase III Healing Read-out eGERD 2nd Phase III 2nd Phase III Healing Read-out Phase I / III H. pylori Undisclosed ILLUSTRATIVE indications First patient in, study NDA/MAA and first regula
Slide 9: Summary of key events Q2, 2024
Summary of key events Q2, 2024 • Successful investor roadshows and completion of IPO • SEK 715m before cost raised on Nasdaq Stockholm, midcap • Market cap approx. SEK 1.5bn, end Aug 2024 • Two of the company’s Phase I studies (BA and PK/PD) were completed during the period. • The PK/PD study have b
Slide 10: Post period highlights
Post period highlights • The Swiss company PSI CRO will serve as the clinical research organization (CRO) for the Phase III program for the treatment of eGERD. • Study medications for phase 3 with the new further developed and better formulation under production. 10
Slide 11: Co-workers
Co-workers 26 Co-workers 12 employees 14 in-house consultants 11
Slide 12: Financial overview, Income statement Jan-Jun 2024
Financial overview, Income statement Jan-Jun 2024 SEKm Apr-Jun-24 Apr-Jun-23 Dev Q2 Jan-Jun-24 Jan-Jun-23 Dev H1 Jan-Dec-23 Jan-Mar-24 Net sales 0,0 3,0 -3,0 0,0 6,0 -6,0 6,0 0,0 G&A -16,7 -12,4 -4,3 -22,3 -24,8 3 -40 -5,6 R&D -20,8 -39,3 18,5 -51,3 -79,0 28 -167 -30,5 Other op exp/income 0,2 -1,4 1
Slide 13: Financial overview, Financial position and Cash flow Jan-Jun 2024
Financial overview, Financial position and Cash flow Jan-Jun 2024 SEKm Jun 30, -24 Jun 30, -23 Dev Dec 31, -23 Fixed assets 0,9 0,3 0,6 0,3 Other Current assets 5,2 15,4 -0,9 6,1 Cash 684,7 108,6 596,7 88,0 Total assets 690,8 124,4 596,4 94,4 Equity 637,8 29,3 714,6 -76,8 Non-current liabilities 6,8
Slide 14: Largest shareholders end of June 2024
Largest shareholders end of June 2024 Number of shares Share (%) Trill Impact Ventures 3 721 221 8,0% Fjärde AP-fonden 3 522 368 7,6% IPO Cornerstone investors: Linc AB 2 114 322 4,5% - Trill Impact Ventures Peter Unge via company 2 050 015 4,4% - 4th AP fund Kjell Andersson via company 1 908 000 4,
Slide 15: Linaprazan Glurate: the next gold-standard in healing erosive GERD
Linaprazan Glurate: the next gold-standard in healing erosive GERD 1 Next generation PCAB targeting healing, the area of high unmet medical need in severe eGERD 2 Phase III ready, clear FDA regulatory pathway, first phase III readout in 2026 3 Superior acid control profile delivering fastest onset o
Slide 16: Calendar
QA Calendar Q3 Report 2024, 14th November 2024 Year-End Report 2024, 20th February 2025 IR contact ir@cincluspharma.com 16